Pfizer said Monday that it will begin disclosing payments to health-care professionals for consulting, speaking engagements, and clinical trials. The drugmaker is making the move after learning of proposed legislation—the company hopes to also boost trust in its products and collaborations.
“This makes Pfizer the first biopharmaceutical company to commit to reporting payments for conducting Phase I to Phase IV clinical trials, in addition to disclosing payments for speaking and consulting,” Pfizer said in a statement.